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Private insurance plays a minor role in paying for pharmaceuticals in New Zealand, despite controversy about
access through the public health system. The present study examines New Zealand consumers’ perceptions of
private insurance for pharmaceuticals. A self-administered questionnaire was completed by 433 consumers at thirty
pharmacies. The questionnaire included 18 questions on demographics, insurance status, perceptions of private
insurance for pharmaceuticals and confidence in the public health system. Forty six percent of respondents had
private health insurance. Respondents were more likely to have private health insurance as household income
increased, and confidence in the public health system decreased. (Over two thirds of respondents were either
confident or very confident in the public health system). Nineteen percent had private health insurance for
pharmaceuticals, and the likelihood was not affected by household income or confidence in the public health
system. Sixty one percent believed private insurance for pharmaceuticals would increase availability and affordability of
pharmaceuticals. However, just over half were willing to pay for private insurance for pharmaceuticals. Of these, over
two thirds were only willing to pay $20 per year or less. New Zealand pharmacy consumers’ willingness to pay for
private insurance for pharmaceuticals is very low.Introduction
Private insurance pays for a mere 2% of pharmaceutical
costs in New Zealand (The Organisation for Economic
Co-operation and Development 2010a). In contrast, pri-
vate insurance pays for 17% of outpatient pharmaceutical
costs in France, and 30% in Canada and the United States
(The Organisation for Economic Co-operation and Devel-
opment 2010b). New Zealand’s per capita pharmaceutical
expenditure is also lower than such countries. In 2010 this
was 288 United States Dollars Purchasing Power Parity
(US$ PPP), compared with 637 US$ PPP in France, 739
US$ PPP in Canada and 973 US$ PPP in the United
States (The Organisation for Economic Co-operation
and Development 2013).
New Zealanders pay for approximately 30% of pharma-
ceutical costs out-of-pocket, a figure which includes pre-
scription charges, prescription medicines that are not
publically funded, and non-prescription medicines. The
proportion of out-of-pocket spending in New Zealand is* Correspondence: z.babar@auckland.ac.nz
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in any medium, provided the original work is phigher than in France, Canada or the United States (The
Organisation for Economic Co-operation and Development
2011). Increasing levels of private insurance for pharma-
ceuticals may therefore both supplement public pharma-
ceutical spending and reduce out-of-pocket expenditures.
In the present study, we examine New Zealanders’ percep-
tions of private insurance coverage for pharmaceuticals.
One possible reason private insurance currently plays
such a small role is that New Zealanders have access to
a wide range of publically funded pharmaceuticals. All
pharmaceuticals used in hospitals are provided free of
charge to the patient. New Zealand also has a national
list of several hundred publically funded cancer and out-
patient pharmaceuticals (estimated at 471 chemical entities
in 2007), which are listed in the Pharmaceutical Schedule.
Over 85% of pharmaceuticals in the Schedule are fully
subsidised, with most patients only paying a NZ $3 (US
$2.2) prescription charge per three month supply of
each pharmaceutical at the time of data collection. (The
prescription charge increased to NZ $5 in 2013) (New
Zealand Ministry of Health 2013; Aaltonen et al. 2010;
Cumming et al. 2010). The remaining pharmaceuticalsis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ing the difference in addition to the prescription charge
(Aaltonen et al. 2010; Cumming et al. 2010).
New Zealand’s strategy of providing a wide range
of publically funded pharmaceuticals at low cost to
patients depends heavily on the effectiveness of the
New Zealand Pharmaceutical Management Agency
(PHARMAC). PHARMAC has been held up as an ex-
ample of how to increase access to pharmaceuticals while
containing pharmaceutical costs (Cumming et al. 2010;
Braae et al. 1999). PHARMAC manages a capped yearly
budget for all pharmaceuticals on the Schedule. This in-
cludes conducting clinical and cost effectiveness evalua-
tions of new pharmaceuticals that manufacturers want
listed on the schedule, carrying out price negotiations with
manufacturers, and setting the conditions under which
pharmaceuticals listed on the Schedule will be subsidised
(The New Zealand Ministry of Health 2014; The New
Zealand Pharmaceutical Management Agency 2013).
PHARMAC also negotiates national prices for many hos-
pital pharmaceuticals, though the assessment and priori-
tisation of hospital pharmaceuticals was done individually
by the country’s 20 District Health Boards (DHBs) at the
time of data collection. The New Zealand Government
has recently expanded PHARMAC’s role to include the
assessment and prioritisation of hospital pharmaceuticals,
and eventually also medical devices (Tordoff et al. 2005;
Tordoff et al. 2008; Ryall 2013). These changes are likely
to make PHARMAC an increasingly dominant part of
New Zealand’s public health system.
However, PHARMAC is also arguably the most con-
troversial part of New Zealand’s public health system. It
has faced criticism for denying New Zealanders timely
access to expensive but potentially life-saving pharmaceu-
ticals (Isaacs et al. 2007). A report to the Government on
access to high cost and highly specialised pharmaceuticals
concluded that New Zealanders’ access to these pharma-
ceuticals lagged behind that in many other Organization
for Economic Co-operation and Development (OECD)
countries. (McCormack et al. 2013). International compar-
isons have shown also shown that New Zealand’s access to
newly launched pharmaceuticals lags behind countries
such as Finland, Australia, the United Kingdom and the
United States (Aaltonen et al. 2010; Ragupathy et al. 2012;
Raftery 2008).
In light of these controversies and concerns about ac-
cess, it is worth examining if New Zealand consumers
are willing to pay for alternatives to the public health
system. The high cost of many new pharmaceuticals
(which can be tens or hundreds of thousands of dollars
per year) mean that paying for non-publically funded
medicines out-of-pocket is unrealistic for all except the
most wealthy (Canadian Cancer Society 2009). Private
insurance for pharmaceuticals as in countries such asFrance, Canada and the United States is a possible
alternative.
Methods
Ethics approval was obtained from the University of
Auckland Human Participants Ethics Committee. The
study is a survey of pharmacy consumers in Auckland,
New Zealand. Copies of the survey instrument, participant
information sheets, participant consent forms, pharmacist
information sheets and pharmacist consent forms are
available from the authors on request.
The survey was conducted using a self-administered
questionnaire. The survey instrument was developed for
this study. The initial draft of the questionnaire was pilot
tested on 10 individuals (of different ages and ethnic
backgrounds, and who had no specialist knowledge of
the health system) to test for comprehensibility and valid-
ity. The questionnaire was modified based on this testing,
and pilot tested on a further ten individuals. Following this
testing, the questionnaire was modified slightly before
being approved by all the authors.
The final questionnaire contained 18 questions, and
was divided into four parts. These were: demographics
(age, gender, ethnicity, occupation, education and house-
hold income), current health status (including use of
medicines and spending on medicines), current insur-
ance status, and perceptions of the public health system.
A list of all pharmacies in the Auckland region was ob-
tained from the Pharmaceutical Society of New Zealand. A
random number generator was used to draw 80 pharmacies
from this list. (The investigational plan called for a survey
of 30 pharmacies, but 80 were selected initially to account
for those who might decline to take part). Initial contact
was by telephone, and those pharmacies which were willing
to take part were sent pharmacist information sheets and
consent forms (with the option of again declining to take
part once they had a chance to read these). Recruitment
stopped when 30 pharmacies had given written consent to
take part in the survey.
A study member was at each of the participating phar-
macies from 10 AM to 5 PM Monday through to Friday.
Every second customer was approached to take part, and
if the customer declined to take part, the next available
customer was approached. If the customer gave verbal
consent to take part, they were then given the participant
information sheet and consent form to read and sign be-
fore being given the questionnaire. The study member
was on hand to explain any questions participants had dif-
ficulty with, but participants were also given the option of
skipping any questions they didn’t want to answer.
Approximately 60% of those approached took part.
There were 433 respondents in total (The characteristics
of those who took part are in Table 1). SPSS statistical
software was used to process the data.
Table 1 Characteristics of survey participants
Frequency Percent
Gender Male 172 39.7
Female 261 60.3










Occupation Self Employed 10 2.4
Unemployed 13 3.1
Professional 162 38.1
Technician / Trade worker 40 9.4
Retail and administration 56 13.2
Labourer 20 4.7




Education None 5 1.1
Primary School 8 1.8
Secondary School 149 33.9
Tertiary Education 184 41.8
Post Graduate 94 21.4
Household income Less than 10,000 32 7.8
10,000 - 30,000 57 13.9
30,001 - 50,000 79 19.3
50,001 - 70,000 71 17.3
70,001 - 90,000 66 16.1
90,000 + 105 25.6




Visits to Pharmacy Once a week or more 25 5.7
Once a month 140 31.7
Once every 3 months 172 38.9
Once every 6 months or more 105 23.8
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participants, compared to the general population of
Auckland in the 2006 Census (Statistics New Zealand2014a). The over-representation of female customers
among survey respondents replicates that in a separate
study of Auckland pharmacy customers (which used
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and respondents) (Babar et al. 2010), and may therefore
reflect the underlying demographics of weekday daytime
Auckland pharmacy customers.
The proportion of Asian (including Indian) respondents
was similar to that of the Auckland population in the
2006 Census (Statistics New Zealand 2014a). Maori and
Pacific respondents are under-represented compared to
the Auckland population, and this may reflect previous
findings that Maori and Pacific people are more likely to
forgo collecting prescriptions (and by implication visiting
a pharmacy) because of cost (Jatrana et al. 2011). Con-
versely, Europeans were over represented. It should be
noted matching ethnicity precisely to the Census is diffi-
cult, as the Census allows the selection of multiple eth-
nic identities, and includes ‘New Zealander’ as an option
(Statistics New Zealand 2014b).
The age distribution of survey respondents was similar to
that of the general Auckland population. Similarly, work-
force participation characteristics (employed, unemployed,
and those not in the labour force such as students, retirees
and housewives) was similar to the general Auckland popu-
lation (Statistics New Zealand 2014a).
Results
Private insurance coverage
Forty six percent of respondents had private health insur-
ance, of whom 42% (19% of all respondents) had private
health insurance coverage for pharmaceuticals. Eighty four
percent of those with private insurance coverage paid for
the insurance themselves or had the insurance paid for by
a family member, while 16% had the insurance paid for by
an employer.
Sixty five percent believed private health insurance
should be subsidised by the government, and 72% stated
that they would be more likely to purchase private
health insurance if it were subsidised.
Chi square analysis showed none of age, gender, ethni-
city or level of education had a statistically significant ef-
fect on whether respondents had private health insurance.
Similarly, the number of visits to a pharmacy, average
monthly spends at a pharmacy, or whether patients were
on medicines that weren’t publically funded had no effect
on whether respondents had private insurance.
The only factors that had significant effects on whether
respondents had private health insurance or not were
household income and confidence in the public health
system. As household income increased, respondents
were more likely to have private insurance coverage (chi
square test p <0.001), odds ratio of 1.510 (95% CI 1.296 –
1.758). As confidence in the public health system in-
creased, respondents were less likely to have private health
insurance (chi square test p 0.044), odds ratio 0.633 (95%
CI = 0.633 – 0.944).Beliefs regarding private insurance for pharmaceuticals
Sixty one percent of respondents believed having private
insurance for pharmaceuticals would increase the avail-
ability and affordability of pharmaceuticals. However,
only 52% were willing to pay extra for private insurance
coverage of pharmaceuticals. Of these, 67% were only
willing to pay $20 or less per year, and only 7% were
willing to pay over $40 per year.
The most common reasons respondents cited for
being willing to pay more for private coverage were
convenience (any medicine that was needed would be
covered), and as a precaution in case they developed
serious illnesses later in life. The types of medicines
patients were most likely to want covered by private
insurance were those for cardiovascular disease (69%
of respondents), cancer (67%), respiratory conditions
(65%) and skin conditions (53%).
The most common reasons respondents cited for be-
ing unwilling to pay more for private insurance coverage
were that the costs of insurance were too high, that they
wouldn’t need it as they didn’t use medicines regularly,
or that it would be more cost effective to pay the $3 pre-
scription charges rather than the insurance premiums.
Chi square analysis show no statistically significant re-
lationships between any of age, gender, ethnicity, level of
education, household income or confidence in the public
health system, and whether respondents were willing to
pay for private insurance coverage for pharmaceuticals.
Similarly, there was no relationship between the number
of visits to a pharmacy, average spending in a pharmacy,
or whether patients were on medicines that weren’t sub-
sidised by the public health system, and whether respon-
dents were willing to pay for private insurance coverage
of pharmaceuticals.Confidence in the public health system
Eighty percent of respondents had experienced no prob-
lems with the public funding of their prescription phar-
maceuticals in the previous 12 months. Eight percent
had problems with funding changes (such as a change in
which brand of a pharmaceutical was funded), 6% had
experienced problems with the availability of pharma-
ceuticals, and 5% had problems with the affordability of
pharmaceuticals.
Ten percent of respondents had delayed getting a pre-
scription filled in the previous 12 months because of
cost. Of these, 88% believed they would be more likely
to have it filled if they had had a private insurance plan
that covered pharmaceuticals (p <0.001).
Twenty seven percent of respondents were very confident
in the public system, and 40% were confident. 15% were
not confident in the public system, with the remainder
being neutral.
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The current study suggests that Auckland pharmacy con-
sumers’ willingness to pay for private insurance coverage
for pharmaceuticals is very low. Just over half of all re-
spondents were willing to pay for such coverage, and of
these 67% were only willing to pay $20 per year or less.
These results of course need to be interpreted in light
of some limitations. This was a survey of ambulatory
pharmacy customers, and as such the responses may not
represent those of people who are severely ill or dis-
abled, and therefore may not be able to visit a pharmacy.
The survey was also done entirely in the city of Auck-
land, and as such the views of the respondents may not
be totally representative of those in New Zealand as a
whole. However, Auckland is home to a quarter of the
New Zealand population, is ethnically and socioeconom-
ically diverse, and draws internal migrants from all over
New Zealand. New Zealand has a unitary system of
Government (including national health, taxation and
legal systems), which makes regional differences in the
costs and benefits of having private insurance unlikely.
This reluctance to pay for private insurance may sim-
ply be a rational response to low prescription costs in
New Zealand. The average prescription cost per patient
per year was $19 in 2007, and had in fact declined from
$24.30 (Cumming et al. 2010). As many respondents in-
dicated, it may be more cost effective to pay prescription
charges than insurance premiums.
Similarly, reluctance to pay for coverage may be due
to consumers perceiving that their risk of being exposed
to catastrophic pharmaceutical costs is relatively low.
The public health system in New Zealand caps prescrip-
tion charges at 20 charges per family per year, which
means even a family with several members who need
multiple medications a year would only pay a maximum
of $60 per year if all pharmaceuticals are fully funded.
(Cumming et al. 2010; The New Zealand Ministry of
Health 2013a). Additional income and usage related safety
nets can reduce prescription charges from $3 to $2 or
even $0 (The New Zealand Ministry of Health 2013b)
(The New Zealand Ministry of Health 2013c).
These safety nets do not protect against the cost of un-
funded pharmaceuticals. However, agencies outside the
public health system can in some cases assist with pharma-
ceutical costs. The Accident Compensation Corporation
(a publically funded and administered insurance scheme)
in some cases pays for pharmaceuticals to treat injuries
resulting from accidents (New Zealand Accident Compen-
sation Corporation (ACC) 2013). Publically funded disabil-
ity payments are also available to assist with some medical
costs (New Zealand Work and Income 2013). Perhaps
as a result of these safety nets, fewer than 3% of New
Zealanders face out-of-pocket pharmaceutical costs of US
$1000 or more per year (The Commonwealth Fund 2013).Ten percent of respondents had deferred collecting a
prescription in the previous 12 months because of cost,
a figure that is at the higher end of the range found in
past studies (The Commonwealth Fund 2013; Jatrana
and Crampton 2009). It is concerning this percentage
hasn’t decreased despite Government efforts to improve
access to primary healthcare. This group of respondents
would have been more likely to collect their prescriptions
if they had private insurance coverage for pharmaceuticals.
However, past studies have shown that New Zealanders
with lower incomes were more likely than to delay col-
lecting their prescriptions (Jatrana and Crampton 2009).
Our results show that this same group is less likely to
have private insurance. Private insurance for pharma-
ceuticals is therefore unlikely to solve access problems
in this group.
Another possible reason for consumers’ reluctance to
pay for private coverage for pharmaceuticals is confidence
the public health system will be able to provide the appro-
priate pharmaceuticals when needed. Overall, 67% of
respondents were either confident or very confident in
the public health system. Interestingly, respondents were
more likely to have private insurance as their confidence
in the public system decreased, but not more likely to be
willing to pay for pharmaceutical cover through private
insurance. This raises the intriguing possibility that despite
the controversy PHARMAC generates, consumers may
have come to trust the PHARMAC centred system can
deliver what they need. Future work that explores this
further may be beneficial.
To the best of our knowledge, this is the first study to
examine New Zealand pharmacy consumers’ attitudes
towards private insurance for pharmaceuticals. As such,
it adds a further piece to the puzzle of how to provide
New Zealanders with affordable access to new (and in-
creasingly expensive medicines) while containing the
total cost to the taxpayer.Conclusion
While the majority of pharmacy consumers believe having
private insurance for pharmaceuticals would increase the
availability and affordability of pharmaceuticals, willing-
ness to pay was low. Slightly more than half were willing
to pay extra for pharmaceutical coverage, of whom about
two thirds were willing to pay $20 or less per year for such
coverage. This may in part be due to the coverage pro-
vided by the public health system, in which again about
two thirds of respondents were either confident or very
confident.
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